No­vo Nordisk gets PhI­II he­mo­phil­ia tri­als for a Roche ri­val back on track af­ter com­plet­ing work-around on blood clot threat

Af­ter abrupt­ly shut­ting down three he­mo­phil­ia stud­ies back in March due to se­ri­ous safe­ty is­sues, No­vo Nordisk is get­ting things go­ing again.

The Dan­ish …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.